AstraZeneca moves deeper into cell therapy with $1bn EsoBiotec acquisition
AstraZeneca’s $1 billion acquisition of EsoBiotec signals a major shift in cell therapy innovation. Find out how this deal could transform cancer treatment. Read More
4D Molecular Therapeutics strengthens cash position, eyes Phase 3 success for 4D-150
4D Molecular Therapeutics (4DMT) has announced its full-year 2024 financial results, highlighting key advancements in its late-stage clinical pipeline. With a primary focus on its ... Read More
Pacira BioSciences strengthens gene therapy pipeline with GQ Bio takeover
Pacira BioSciences, Inc. has taken a significant step toward expanding its presence in genetic medicine by acquiring the remaining 81% equity stake of GQ Bio ... Read More
MeiraGTx’s gene therapy trial shows transformative results for children with LCA4 retinal dystrophy
MeiraGTx Holdings plc has announced groundbreaking results from its gene therapy trial targeting Leber congenital amaurosis 4 (LCA4), a severe and rare form of retinal ... Read More
Newbiologix launches advanced rAAV platform for gene therapy production
NewBiologix, a Swiss technology innovation company specializing in cell and gene therapy production solutions, has introduced its cutting-edge Xcell rAAV Production and Analytics Platform (Xcell ... Read More
Gamma Biosciences to sell Mirus Bio to Merck KGaA for $600m in key biotech deal
Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading global science and technology company, has agreed to acquire Mirus Bio from Gamma Biosciences for $600 million in ... Read More
Pfizer secures FDA approval for Hemophilia B gene therapy BEQVEZ
Pfizer Inc. (NYSE: PFE) announced a significant breakthrough in hemophilia treatment with the U.S. Food and Drug Administration's approval of BEQVEZ (fidanacogene elaparvovec-dzkt), a pioneering ... Read More
RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its ... Read More
Merck announces over €300m investment in new bioprocessing center in South Korea
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, ... Read More
Ginkgo Bioworks acquires Proof Diagnostics to boost cell programming and biosecurity capabilities
Ginkgo Bioworks, a leader in cell programming and biosecurity, announced its acquisition of Proof Diagnostics, a trailblazer in life sciences tools, diagnostics, and computational discovery. ... Read More